DENDREON REPORTS PRELIMINARY D9902A TRIAL DATA FOR PROVENGE IN PATIENTS WITH ADVANCED PROSTATE CANCER

Dendreon has released the preliminary data from its D9902A study of Provenge, the company's investigational immunotherapy for the treatment of advanced prostate cancer.

The final analysis of the primary endpoint, time to disease progression, in D9902A did not show a statistically significant delay in time to disease progression in the overall group or in the Gleason score subgroups.

An interim analysis of overall survival in the intent-to-treat patient population, the secondary endpoint of the D9902A study, indicated that both the survival rates and the median survival benefit compared to placebo are similar to the results observed in the final three-year survival analysis of the D9901 study reported in October 2004.

The results from the D9901 study demonstrated a survival benefit in the overall intent-to-treat patient population. The company plans to complete the final prespecified, three-year survival analysis of the D9902A study in the second half of 2005. As in previous studies, Provenge was generally well-tolerated.